Cardio3 BioSciences SA, which has an autologous cell therapy for patients with chronic heart failure in the clinic, has raised €19 million in a private placement with existing investors to finance the clinical development of its lead product. ---Subscribe to MedNous to access this article--- Regenerative Medicine Company News Finance, Grants, Deals
